ScholarLens Back to search
1995•Beiträge zur Onkologie/Contributions to oncologyRequires access

Antibody-Directed Enzyme Prodrug Therapy

Richard J. Knox

Open publisher page 11 citations

Abstract

Antibody-directed enzyme prodrug therapy (ADEPT) is a new approach to the treatment of solid cancers. In ADEPT, an antibody (or antibody fragment) is conjugated to an enzyme and is used to localise the enzyme at the site of the tumour. Once localised, the enzyme is used to activate a noncytotoxic prodrug to an active cytotoxic form. Therapy can proceed in either 2 or 3 phases. In the 2-phase system, the nonlocalised unbound antibody-enzyme conjugate is allowed to clear naturally from the body, and then the prodrug is administered. In the 3-phase system, clearance of unbound conjugate is accelerated by a ‘clearance’ antibody.

About this research paper

What this paper is about

Antibody-directed enzyme prodrug therapy (ADEPT) is a new approach to the treatment of solid cancers. In ADEPT, an antibody (or antibody fragment) is conjugated to an enzyme and is used to localise the enzyme at the site of the tumour. Once localised, the enzyme is used to activate a noncytotoxic prodrug to an active cytotoxic form. Therapy can proceed in either 2 or 3 phases. In the 2-phase system, the nonlocalised unbound antibody-enzyme conjugate is allowed to clear naturally from the body, and then the prodrug is administered. In the 3-phase system, clearance of unbound conjugate is accelerated by a ‘clearance’ antibody.

Why it matters

OpenAlex reports 11 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Antibody-directed enzyme prodrug therapy (ADEPT) is a new approach to the treatment of solid cancers. In ADEPT, an antibody (or antibody fragment) is conjugated to an enzyme and is used to localise the enzyme at the site of the tumour. Once localised, the enzyme is used to activate a noncytotoxic prodrug to an active cytotoxic form. Therapy can proceed in either 2 or 3 phases. In the 2-phase system, the nonlocalised unbound antibody-enzyme conjugate is allowed to clear naturally from the body, and then the prodrug is administered. In the 3-phase system, clearance of unbound conjugate is accelerated by a ‘clearance’ antibody.

Key concepts: Prodrug, Adept, Antibody, Antibody therapy, Medicine, Enzyme, Pharmacology, Immunology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Antibody-Directed Enzyme Prodrug Therapy — Research Paper | ScholarLens